BSE filing, NSE: JENBURPH. Summary written from the filing by ALFA Finder's alert engine.
Jenburkt Pharmaceuticals Ltd: key numbers
- Share price
- ₹870.00
- Market cap
- ₹384.0 Cr
- Revenue (annual)
- ₹168.7 Cr
- Net profit (annual)
- ₹34.74 Cr
- P/E (TTM)
- 11.7×Sector 46.1×
- Promoter holding
- 46.62%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jenburkt Pharmaceuticals Ltd
All →Jenburkt Pharmaceuticals Capital Structure Change
Counter Cyclical Investments Private Limited acquired 326 shares of Jenburkt Pharmaceuticals Ltd in the open market, increasing its total shareholding from 4.99% to 5.01%.
Jenburkt Pharmaceuticals Other Announcement
Jenburkt Pharmaceuticals submitted a certificate under SEBI Regulation 74(5) regarding share dematerialization for the quarter ended September 30, 2026.
Jenburkt Pharmaceuticals Other Announcement
Jenburkt Pharmaceuticals clarified its shares are permitted to trade on NSE without a listing application. The shares remain listed on BSE under the Permitted to Trade category.
Jenburkt Pharmaceuticals Management Change
Mr. Vinay Bhatt, Senior Vice President- International Business, has resigned from Jenburkt Pharmaceuticals Limited effective September 18, 2026, due to personal reasons.
Jenburkt Pharmaceuticals Annual General Meeting
Jenburkt Pharmaceuticals held its 41st Annual General Meeting on 4th September, 2026, to discuss financial statements, dividend declaration, and director appointments.
Jenburkt Pharmaceuticals Management Change
Jenburkt Pharmaceuticals elevated Shri Prem Ashish Bhuta to Associate Vice President – Strategic Initiatives. He is now classified as Senior Management Personnel effective September 4, 2026.
Other board meeting date announcements
All →Sigma Solve Board Meeting Date
SIGMA SOLVE LIMITED will hold a board meeting on 03 Nov 2026 to consider unaudited standalone and consolidated results for the quarter ended September 2026. Investors should await the results filing.
Siddhi Cotspin Board Meeting Date
Siddhi Cotspin will hold a board meeting on 04-Nov-2026 to consider unaudited half-yearly results. Trading window closes until 07-11-2026.
Agarwal Fortune India Board Meeting Date
Agarwal Fortune India Ltd intimated BSE of a board meeting on 04 November 2026 to consider unaudited Q2 and half-year results ended September 30, 2026. The trading window stays closed until 06 November 2026.
Latteys Industries Board Meeting Date
Latteys Industries will hold a board meeting on 5 November 2026 to consider unaudited standalone Q2 results. Trading window closes 1 October to 7 November 2026.
Binny Mills Board Meeting Date
Binny Mills will hold a board meeting on November 6, 2026 to consider unaudited standalone half-yearly results. The trading window stays closed until November 8, 2026.
Shanti Gold International Board Meeting Date
Shanti Gold will hold a board meeting on November 3, 2026 to consider unaudited results. The trading window remains closed until 48 hours after results.